In a groundbreaking move, Cardio Diagnostics Holdings, Inc. (NASDAQ: CDIO) has inked a new deal with Navierre, an innovative digital health technology platform, to make its industry-leading, AI-enabled precision cardiovascular diagnostic tests more widely available to patients and clinicians nationwide.
Through this strategic partnership, Cardio Diagnostics’ precision heart health solutions, including its flagship AI-powered epigenetic-genetic cardiovascular risk, detection, and management tests, Epi+Gen CHD and PrecisionCHD, are now accessible to thousands of patients and clinicians on Navierre’s platform. Navierre-partnered clinicians across the United States can seamlessly order these tests for their patients, while consumers can easily register for a profile on the platform and request a test.
Meesha Dogan, Ph.D., CEO and Co-Founder of Cardio Diagnostics, expressed her enthusiasm for the partnership, stating, ‘We are thrilled to partner with Navierre to make our industry-leading cardiovascular clinical tests more widely available to patients and clinicians nationwide. Navierre’s innovative platform aligns with our mission to transform cardiovascular care through AI-driven precision diagnostics and personalized prevention strategies.’
The collaboration comes at a critical time, as the demand for cardiovascular diagnostics has never been higher. According to the Centers for Disease Control and Prevention (CDC), nearly 50% of Americans live with diabetes, obesity, hypertension, or another major cardiovascular risk. Cardiovascular disease is the leading cause of death worldwide, accounting for nearly 19 million deaths annually.
Mustafa Dinani, CEO and co-founder of Navierre, shared his excitement about the partnership, stating, ‘Cardio Diagnostics’ groundbreaking testing solutions are an exciting addition to our curated list of products and services we offer to our users. By combining our innovative platform with their AI-driven precision diagnostics, we empower patients and clinicians with the tools they need to identify cardiovascular risk early when it can be most effectively addressed. Together, we are making significant strides in the fight against the world’s leading cause of death.’
This collaboration directly responds to the limitations of current diagnostic methods, offering a scalable solution that extends to remote zip codes in the U.S. By expanding the sites of care to telehealth and remote-enabled provider organizations, the partnership aims to address the critical issue of increasing wait times for specialty care while democratizing access to top-tier heart disease services.
The partnership between Cardio Diagnostics and Navierre is poised to capitalize on the growing trends in the healthcare landscape, including the surge in digital health, telehealth, and AI-driven diagnostics. With the flexibility of Cardio Diagnostics’ tests and Navierre’s innovative platform, this collaboration has the potential to make a significant impact in the fight against cardiovascular disease, a leading cause of death worldwide.
}
This news story relied on a press release distributed by News Direct. Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is Cardio Diagnostics Partners with Navierre to Expand Access to Cutting-Edge Cardiovascular Tests.